Associations between HLA-C alleles and papillary thyroid carcinoma

Cancer Biomarkers

Volumn 5, Issue 1, 2009, Pages 19-22

  Haghpanah, Vahid ^a   Khalooghi, Keinoosh ^a   Adabi, Khadijeh ^a   Amiri, Parvin ^a   Tavangar, Seyed Mohammad ^b   Amirzargar, Ali ^c   Ghaffari, Hamidollah ^c   Yazdani, Nasrin ^c   Nikbin, Behrooz ^c   Larijani, Bagher ^a   Amoli, Mahsa M ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Epidemiology; Genetics; HLA; Papillary carcinoma; Thyroid

Indexed keywords

HLA C ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HLA TYPING; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA;

ADULT; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; HLA-C ANTIGENS; HUMANS; IRAN; MALE; PROGNOSIS; RISK FACTORS; THYROID NEOPLASMS;

EID: 61449172977     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0564     Document Type: Article

References (27)

1. L. Davies and H.G, Welch. Increasing incidence of thyroid cancer in the United States, 1973-2002, JAMA 18 (2006), 2164-2167.
2. W. Klitz, Viruses, cancer and the MHC, Nature 356 (1992), 17-18.
3. M. Browning and D.Dunnion, HLA and cancer: Implications for cancer immunotherapy and vaccination, Eur J Immunogenet 24 (1997), 293-312.
4. C.R. McEvoy, R. Seshadri, A.A. Morley and F.A. Firgaira, Frequency and genetic basis of MHC, beta-2-microglobulin and MEMO-1 loss of heterozygosity in sporadic breast cancer, Tissue Antigens 60 (2002), 235-243.
5. A. Garcia-Lora, I. Algarra, J.J. Gaforio, F. Ruiz-Cabello and F. Garrido, Immunoselection byT lymphocytes generates repeated MHCclass I-deficient metastatic tumor variants, Int J Cancer 91 (2001), 109-119.
6. F. Juhasz, L. Kozma, V. Stenszky, F. Gyory, G. Luckas and N.R. Farid, Well differentiated thyroid carcinoma is associated with human lymphocyte antigen D-related 11 in Eastern Hungarians: A case of changing circumstances, Cancer 15 (2005), 1603-1608.
7. F. Juhasz, P. Boros and G. Szegedi, Immunogenetic and immunologic studies of differentiated thyroid cancer, Cancer 63 (1989), 1318-1326.
8. F. Juhasz, G. Balazs, L. Kozma, E. Kraszits, V. Stenszky and N.R. Farid, Interaction of IgG heavy-chain allotypes (Gm) and HLA in conferring susceptibility to thyroid carcinoma, Clin Endocrinol Oxford 25 (1986), 17-21.
9. N. Panza, L. Del Vecchio, M. Maio et al., Strong association between an HLA-DR antigen and thyroid carcinoma, Tissue Antigens 20 (1982), 155-158.
10. V. Sridama, Y. Hara, R. Fauchet and L.J. DeGroot, Association of differentiated thyroid carcinoma with HLA-DR7, Cancer 56 (1985), 1086-1088.
11. F. Juhasz, G. Balazs, V. Stenszky, L. Kozma and N.R.Farid, The relation of susceptibility to and biologic behavior of thyroid epithelial cell cancer to HLA-DR1, Cancer 56 (1986), 52-54.
12. B. Larsen, C. Thompson, A. Kwan and N.R. Farid, Lack of association of HLA with thyroid cancer, An effect of iodine sufficiency and safe environment? Tissue Antigens 28 (1986), 298-300.
13. H. Dralle, M. Robin-Winn, L. Reilmann, A. Laue and M. Torok, HLA and thyroid cancer, Klin Wochenschr 64 (1986), 522-525.
14. M. Weissel, H. Kainz, R. Hoefer and W.R. Mayr, HLA-DR and differentiated thyroid cancer, Lack of association with the nonmedullary types and possible association with the medullary type, Cancer 62 (1988), 2486-2488.
15. S. Ahuja, I. Hoppe, H. von Keyserlingk and H. Ernst, HLA and thyroid carcinoma, Exp lin Endocrinol 99 (1992), 134-136.
16. D. Rigopoulou, J. Martinez-Laso, F. Martinez-Tello et al., Both Class I and Class II HLA antigens are thyroid cancer susceptibility factors, Tissue Antigens 43 (1994), 281-285.
17. A. Rios, J.M. Rodriguez, M.R. Moya et al., Frequency of HLA-C alleles in differentiated thyroid carcinoma in south-eastern Spain, Cancer 100 (2004), 264-269.
18. G.M. Spaggiari, P. Contini and A. Dondero, et al., Soluble HLA Class I induces NK cell apoptosis upon the engagement of killer-activating HLA Class I receptors through FasL-Fas interaction, Blood 100 (2002), 4098-4107.
19. O. Ozaki, K. Ito, K. Kobayashi, A. Suzuku, Y. Manabe and Y. Hosoda, Familial occurrence of differentiated, nonmedullary thyroid carcinoma, World J Surg 12 (1988), 565-571.
20. L. Heidecker, F. Brasseur, M. Probst-Kepper et al., Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12, J Immunol 164 (2000), 6041-6045.
21. K. Araki, Y. Noguchi T. Hirouchi et al., Cancer regression induced by modified CTL therapy is regulated by HLA Class II and Class I antigens in Japanese patients with advanced cancer, Int J Oncol 17 (2000), 1107-1118.
22. M.J. Simmonds, J.M. Howson, J.M. Heward, J. Carr-Smith, J.A. Franklyn, J.A. Todd and S.C. Gough, A novel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effect, Hum Mol Genet 16 (2007), 2149-2153.
23. A. Ríos, J.M. Rodríguez, M.R. Moya, P.J. Galindo, M. Canteras, M.R. Alvarez and P. Parrilla, Associations of HLA-C alleles with multinodular goiters: Study in a population from southeastern Spain, Arch Surg 141 (2006), 123-128.
24. T.M. Shattuck, W.H. Westra, P.W. Ladenson and A. Arnold, Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma, N Engl J Med 352 (2005), 2406-2412.
25. L.A. Guethlein, A.M. Older Aguilar, L. Abi-Rached and P. Parham, Evolution of killer cell Ig-like receptor (KIR) genes: Definition of an orangutan KIR haplotype reveals expansion of lineage III KIR associated with the emergence of MHC-C, J Immuno, 179 (2007), 491-504.
26. M. Yawata, N. Yawata, M. Draghi, A.M. Little, F. Partheniou and P. Parham, Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function, J Exp Med 203 (2006), 633-645.
27. V. Haghpanah, P. Shooshtarizadeh, R. Heshmat, B. Larijani and S.M. Tavangar, Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma, Appl Immunohistochem Mol Morphol 14 (2006) 422-425.